CliffBio
biologic

Yescarta

axicabtagene ciloleucel

Loss of exclusivityOctober 2029projected — 12-year biologic exclusivity estimate
CompanyKite Pharma →View the full company profile on CliffBio

Drug detail

Brand nameYescarta
Active ingredientaxicabtagene ciloleucel
Strength2 × 10^6 CAR-POSITIVE VIABLE T CELLS PER KG OF BODY WEIGHT
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2017
Marketing statusRx

More from Kite Pharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Yescarta patent cliff — loss of exclusivity October 2029 | CliffBio